AI Article Synopsis
- Haemophilia care in Germany allows patients to live mostly normal lives, with the Bluter Betreuung Bayern e.V. (BBB) dedicated to enhancing healthcare for these individuals.
- A questionnaire sent to 290 patients yielded a 51.4% response rate, revealing that severe cases are notably high across all age groups, with strong adherence to prophylactic and substitution therapies.
- Most patients report high satisfaction with medical care, though chronic pain increases with age; younger patients are less concerned about future health compared to older ones, while the demand for scientific information and psychosocial support remains consistent across all ages.
Article Abstract
Haemophilia care in Germany has achieved a high level and enables the majority of patients to lead a largely normal life. The Bluter Betreuung Bayern e.V. (BBB) aims to improve health care and support for haemophilia patients. A questionnaire has been developed by BBB representatives to evaluate unmet medical needs from the patient perspective. It was sent to 290 haemophilia patients and/or their parents in Bavaria in November 2015. The response rate was 51.4 %: 66 children aged < 15 years (66.7 % severe), 30 patients 15-24 years (66.7 % severe), 26 patients 25-44 years (80.8 % severe), 24 patients > 44 years (95.8 % severe). Prophylactic therapy in patients with severe haemophilia aged < 25 and ≥ 25 years is given "always" in ≥ 80 % and > 60 %, respectively. Substitution therapy is mostly uncomplicated. Satisfaction with medical care is high. Chronic pain is a problem with increasing age. Patients aged 25-44 years worry least regarding future health, safety and availability of factor products, patients > 44 years most. Overall, 80-100 % of the patients from all age groups are interested in information on the current state of science. Offers of the BBB for psychosocial support in addition to the medical care seem to be helpful and needed in all age groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5482/HAMO-16-09-0033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transfusion in trauma: empiric or guided therapy?
Res Pract Thromb Haemost
January 2025
Oxford Haemophilia and Thrombosis Centre, Department of Haematology, Oxford University Hospitals National Health Service Foundation Trust, Nuffield Orthopaedic Centre, Oxford, UK.
A state of the art lecture titled "Transfusion therapy in trauma-what to give? Empiric vs guided" was presented at the International Society on Thrombosis and Haemostasis Congress in 2024. Uncontrolled bleeding is the commonest preventable cause of death after traumatic injury. Hemostatic resuscitation is the foundation of contemporary transfusion practice for traumatic bleeding and has 2 main aims: to immediately support the circulating blood volume and to treat/prevent the associated trauma-induced coagulopathy.
View Article and Find Full Text PDFSimultaneous total hip and knee arthroplasties in hemophilic arthropathy: series of 5 cases.
Acta Orthop Traumatol Turc
December 2024
Department of Orthopedics and Traumatology, Ege University School of Medicine, Izmir, Türkiye.
Objective: This study aimed to compare preoperative and postoperative measures in haemophiliacs who had simultaneous total hip and knee arthroplasties.
Methods: A retrospective database search identified five patients with severe factor 8 deficiencies who underwent simultaneous hip and knee joint replacement surgery between 2002-2018. Preoperative and postoperative evaluations included Harris Hip Score (HHS), Knee Society Score (KSS), Knee Injury and Osteoarthritis Outcome Score (KOOS), range of motion, flexion contracture (FC), Visual Analog Scale (VAS), hip-knee angle, and leg length discrepancy.
Tooth extraction after transfusion of fresh frozen plasma in a severe factor XI deficiency (hemophilia C) patient.
J Dent Sci
January 2025
Department of Dentistry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France.
Ther Adv Hematol
January 2025
Sobi, Basel, Switzerland.
Background: More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B.
Objectives: We report final data from the B-SURE study, evaluating the real-world usage and effectiveness of rFIXFc in France.
Methods: Previously treated patients (all ages/severities) received on-demand or prophylactic rFIXFc during B-SURE.
Comparison of Single Knee Arthroplasty and Bilateral Knee Arthroplasty in Haemophiliacs During a Single Operation: A Systematic Review and Meta-Analysis.
Haemophilia
January 2025
Department of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Background: Arthroplasty is the standard treatment for end-stage haemophilic knee arthritis; however, the choice between single knee arthroplasty (SKA) and bilateral knee arthroplasty (BKA) in a single operation remains controversial due to the risks specific to haemophiliacs.
Methods: Two independent researchers conducted searches across CNKI, CBM, Wanfang, PubMed, Cochrane Library, Embase, and Web of Science, with the last search performed on 15 October 2024. Study results include joint function, complication and various cost.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!